CDNF is a clinical trial candidate in Parkinson’s disease but the mechanism of action is not fully understood. Here, the authors use SAXS and NMR techniques to resolve the structure of CDNF in complex with GRP78 and show that this interaction is required for the neuroprotective action of CDNF.
- Melissa A. Graewert
- Maria Volkova
- Henri J. Huttunen